The Impact of Fosfomycin on Gram Negative Infections: A Comprehensive Review

Overview

Journal Indian J Microbiol

Specialty Microbiology

Date 2024 Sep 16

PMID 39282196

Authors

Sandeepika Dubey

Areena Hoda Siddiqui

Meenakshi Sharma

Affiliations

Soon will be listed here.

Abstract

Multidrug-resistant or extended drug resistance has created havoc when it comes to patient treatment, as options are limited because of the spread of pathogens that are extensively or multidrug-resistant (MDR or XDR) and the absence of novel antibiotics that are effective against these pathogens. Physicians have therefore started using more established antibiotics such as polymyxins, tetracyclines, and aminoglycosides. Fosfomycin has just come to light as a result of the emergence of resistance to these medications since it continues to be effective against MDR and XDR bacteria that are both gram-positive and gram-negative. Fosfomycin, a bactericidal analogue of phosphoenolpyruvate that was formerly utilised as an oral medication for uncomplicated urinary tract infections, has recently attracted the interest of clinicians around the world. It may generally be a suitable therapy option for patients with highly resistant pathogenic infections, according to the advanced resistance shown by gram-negative bacteria. This review article aims to comprehensively evaluate the impact of fosfomycin on gram negative infections, highlighting its mechanism of action, pharmacokinetics, clinical efficacy, and resistance patterns.

Citing Articles

Mechanisms, therapeutic strategies, and emerging therapeutic alternatives for carbapenem resistance in Gram-negative bacteria.

Mourabiti F, Jouga F, Sakoui S, El Hosayny O, Zouheir Y, Soukri A Arch Microbiol. 2025; 207(3):58.

PMID: 39948320 DOI: 10.1007/s00203-025-04252-z.

References

Fillgrove K, Pakhomova S, Newcomer M, Armstrong R . Mechanistic diversity of fosfomycin resistance in pathogenic microorganisms. J Am Chem Soc. 2003; 125(51):15730-1. DOI: 10.1021/ja039307z. View

Wilke M, Grube R . Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy. Infect Drug Resist. 2014; 7:1-7. PMC: 3872224. DOI: 10.2147/IDR.S25985. View

Corvec S, Furustrand Tafin U, Betrisey B, Borens O, Trampuz A . Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother. 2013; 57(3):1421-7. PMC: 3591882. DOI: 10.1128/AAC.01718-12. View

Lepe J, Torres M, Smani Y, Parra-Millan R, Pachon J, Vazquez-Barba I . In vitro and intracellular activities of fosfomycin against clinical strains of Listeria monocytogenes. Int J Antimicrob Agents. 2013; 43(2):135-9. DOI: 10.1016/j.ijantimicag.2013.10.018. View

KAHAN F, Kahan J, Cassidy P, KROPP H . The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974; 235(0):364-86. DOI: 10.1111/j.1749-6632.1974.tb43277.x. View

Grossato A, Sartori R, Fontana R . Effect of non-beta-lactam antibiotics on penicillin-binding protein synthesis of Enterococcus hirae ATCC 9790. J Antimicrob Chemother. 1991; 27(3):263-71. DOI: 10.1093/jac/27.3.263. View

Rodriguez-Avial C, Rodriguez-Avial I, Hernandez E, Picazo J . [Increasing prevalence of fosfomycin resistance in extended-spectrum-beta-lactamase-producing Escherichia coli urinary isolates (2005-2009-2011)]. Rev Esp Quimioter. 2013; 26(1):43-6. View

Popovic M, Steinort D, Pillai S, Joukhadar C . Fosfomycin: an old, new friend?. Eur J Clin Microbiol Infect Dis. 2009; 29(2):127-42. DOI: 10.1007/s10096-009-0833-2. View

Kuzuyama T, Kobayashi S, Ohara K, Hidaka T, Seto H . Fosfomycin monophosphate and fosfomycin diphosphate, two inactivated fosfomycin derivatives formed by gene products of fomA and fomB from a fosfomycin producing organism Streptomyces wedmorensis. J Antibiot (Tokyo). 1996; 49(5):502-4. DOI: 10.7164/antibiotics.49.502. View

10.

Grabein B, Graninger W, Rodriguez Bano J, Dinh A, Liesenfeld D . Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2016; 23(6):363-372. DOI: 10.1016/j.cmi.2016.12.005. View

11.

Del Rio A, Gasch O, Moreno A, Pena C, Cuquet J, Soy D . Efficacy and safety of fosfomycin plus imipenem as rescue therapy for complicated bacteremia and endocarditis due to methicillin-resistant Staphylococcus aureus: a multicenter clinical trial. Clin Infect Dis. 2014; 59(8):1105-12. DOI: 10.1093/cid/ciu580. View

12.

Guo Q, Tomich A, McElheny C, Cooper V, Stoesser N, Wang M . Glutathione-S-transferase FosA6 of Klebsiella pneumoniae origin conferring fosfomycin resistance in ESBL-producing Escherichia coli. J Antimicrob Chemother. 2016; 71(9):2460-5. PMC: 4992852. DOI: 10.1093/jac/dkw177. View

13.

Navas J, Leon J, Arroyo M, Garcia Lobo J . Nucleotide sequence and intracellular location of the product of the fosfomycin resistance gene from transposon Tn2921. Antimicrob Agents Chemother. 1990; 34(10):2016-8. PMC: 171982. DOI: 10.1128/AAC.34.10.2016. View

14.

Benachinmardi K, Ravikumar R, Indiradevi B . Role of Biofilm in Cerebrospinal Fluid Shunt Infections: A Study at Tertiary Neurocare Center from South India. J Neurosci Rural Pract. 2017; 8(3):335-341. PMC: 5488550. DOI: 10.4103/jnrp.jnrp_22_17. View

15.

Martinez-Martinez L, Rodriguez G, Pascual A, Suarez A, Perea E . In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii. J Antimicrob Chemother. 1996; 38(6):1107-8. DOI: 10.1093/jac/38.6.1107. View

16.

Bassetti M, Peghin M, Pecori D . The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis. 2016; 29(6):583-594. DOI: 10.1097/QCO.0000000000000314. View

17.

Gutierrez-Gutierrez B, Salamanca E, Cueto M, Hsueh P, Viale P, Pano-Pardo J . Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017; 17(7):726-734. DOI: 10.1016/S1473-3099(17)30228-1. View

18.

Sirot J, Lopitaux R, Dumont C, RAMPON S, CLUZEL R . [Diffusion of fosfomycin into bone tissue in man]. Pathol Biol (Paris). 1983; 31(6):522-4. View

19.

Gasch O, Camoez M, Dominguez M, Padilla B, Pintado V, Almirante B . Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. J Antimicrob Chemother. 2013; 69(2):568-71. DOI: 10.1093/jac/dkt396. View

20.

Castanheira M, Griffin M, Deshpande L, Mendes R, Jones R, Flamm R . Detection of mcr-1 among Escherichia coli Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015. Antimicrob Agents Chemother. 2016; 60(9):5623-4. PMC: 4997847. DOI: 10.1128/AAC.01267-16. View